GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Over the last 12 months, insiders at GeoVax Labs, Inc. have bought $43,421 and sold $0 worth of GeoVax Labs, Inc. stock.
On average, over the past 5 years, insiders at GeoVax Labs, Inc. have bought $46,191 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: DODD DAVID A (President, CEO) — $35,381. Reynolds Mark (CFO) — $5,540. McKee Kelly T. Jr. (Chief Medical Officer) — $2,500.
The last purchase of 8,000 shares for transaction amount of $15,600 was made by DODD DAVID A (President, CEO) on 2024‑08‑09.
2024-08-09 | President, CEO | 8,000 0.1589% | $1.95 | $15,600 | +44.12% | |||
2024-02-22 | President, CEO | 8,209 0.431% | $2.27 | $18,663 | -8.22% | |||
2024-02-21 | President, CEO | 520 0.0257% | $2.15 | $1,118 | -8.64% | |||
2024-02-07 | CFO | 2,000 0.0718% | $2.77 | $5,540 | -21.32% | |||
2023-12-22 | Chief Medical Officer | 6,944 0.0257% | $0.36 | $2,500 | +452.47% | |||
2023-09-25 | Chief Medical Officer | 9,653 0.0371% | $0.52 | $5,020 | +218.67% | |||
2023-08-25 | President, CEO | 35,087 0.1351% | $0.57 | $20,000 | +161.61% | |||
2023-08-18 | CFO | 10,000 0.038% | $0.52 | $5,179 | +171.84% | |||
2023-04-24 | President, CEO | 32,000 0.122% | $0.64 | $20,445 | -10.61% | |||
2023-04-20 | CFO | 8,000 0.0297% | $0.63 | $5,040 | -11.90% | |||
2022-09-21 | director | 10,000 0.043% | $1.10 | $11,000 | -39.22% | |||
2022-07-01 | VP, Business Development | 1,000 0.0043% | $0.82 | $820 | -6.48% | |||
2022-06-27 | Chief Medical Officer | 4,464 0.0367% | $1.12 | $5,000 | -28.60% | |||
2022-06-21 | 10,000 0.0761% | $1.21 | $12,100 | -38.32% | ||||
2022-05-05 | Chief Medical Officer | 9,722 0.0758% | $0.72 | $7,000 | +11.57% | |||
2022-05-04 | Chief Medical Officer | 4,999 0.0362% | $0.71 | $3,549 | +5.19% | |||
2011-12-30 | CSO Emeritus | 149,254 <0.0001% | $0.67 | $100,000 | ||||
2011-12-30 | President, CEO | 112,000 <0.0001% | $0.67 | $75,040 | ||||
2011-12-30 | CFO | 15,000 <0.0001% | $0.67 | $10,050 | ||||
2010-07-02 | CFO | 1,000 <0.0001% | $2.50 | $2,500 |
McKee Kelly T. Jr. | Chief Medical Officer | 35782 0.3792% | $2.34 | 5 | 0 | <0.0001% |
DODD DAVID A | President, CEO | 26661 0.2825% | $2.34 | 9 | 0 | <0.0001% |
Reynolds Mark | CFO | 7213 0.0764% | $2.34 | 9 | 0 | <0.0001% |
EMORY UNIVERSITY | 10 percent owner | 231070253 2448.7975% | $2.34 | 0 | 24 | |
ROBINSON HARRIET L | CSO Emeritus | 1201226 12.7302% | $2.34 | 5 | 8 | |
Tsolinas Peter M | director | 431734 4.5754% | $2.34 | 1 | 0 | |
CHASE RANDAL D | director | 36613 0.388% | $2.34 | 2 | 0 | <0.0001% |
HILDEBRAND DONALD G | director | 19000 0.2014% | $2.34 | 1 | 0 | |
SPENCER JOHN N JR | director | 13700 0.1452% | $2.34 | 4 | 0 | |
MCNALLY ROBERT T | director | 8300 0.088% | $2.34 | 7 | 0 | |
NEWMAN MARK J | Chief Scientific Officer | 3000 0.0318% | $2.34 | 1 | 0 | |
Sharkey John W. | VP, Business Development | 2860 0.0303% | $2.34 | 1 | 0 | <0.0001% |